Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 9737 - 9744 of 11616 results
DOJ Antitrust Enforcers Take to the Bully Pulpit on Prosecuting Antitrust Crimes and Antitrust Compliance Programs
September 12, 2014| Alert| Viewpoint
IRS Affirms Treatment of Short Sales for UBTI Purposes
September 12, 2014| Alert| Viewpoint
SEC Uses Data Analytics to Identify and Punish Late Form Filers
September 12, 2014| Blog| Viewpoint
Upcoming Webinar on September 23, 2014: What Your Company Needs to Know to Protect Itself from FCPA Liability
September 12, 2014| Blog| Viewpoint
NIST Issues Draft Report Enumerating Risks and Protections to Consider When Evaluating Mobile Apps for Your Enterprise
September 12, 2014| Blog| Viewpoint
Upcoming Webinar on October 8th: Wage & Hour Compliance for the Auto Dealer Industry (CLE credit available)
September 11, 2014| Blog| Viewpoint
AB 1103 Update: Postponement of Certain Nonresidential Building Energy Use Disclosure Requirements
September 11, 2014| Alert| Viewpoint
Calling for Judicial/Legislative Intervention in Unwarranted M&A Shareholder Litigation
September 11, 2014| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.